Last updated: November 4, 2026
Buminate and Flexbumin are plasma-derived human albumin products used for volume expansion, hypoalbuminemia-related conditions, and selected critical-care indications. Their commercial outlook is driven less by traditional patent exclusivity than by plasma supply, fractionation capacity, regulatory compliance, hospital contracts, and manufacturing reliability. Public companies do not disclose revenue for either brand separately, so product-level financial trajectories must be assessed through portfolio disclosures, market structure, and supply conditions.
Flexbumin has the stronger current commercial platform because it is part of Takeda's global plasma-derived therapies portfolio. Buminate has a longer commercial history under Baxter and Baxalta but has less visible standalone financial disclosure. Neither product has a conventional small-molecule generic-entry profile.
What are Buminate and Flexbumin?
Buminate and Flexbumin are intravenous human albumin solutions derived from pooled human plasma.
| Product |
Active ingredient |
Common strengths |
Product type |
Historical manufacturer or commercial owner |
| Buminate |
Albumin human |
5%, 25% |
Plasma-derived biologic |
Baxter, later associated with Baxalta and Takeda portfolio transitions |
| Flexbumin |
Albumin human |
5%, 25% |
Plasma-derived biologic |
Baxalta, later Shire and Takeda |
| Albumin human products |
Albumin human |
4%, 5%, 20%, 25% and other regional strengths |
Plasma-derived biologic |
Multiple manufacturers globally |
Albumin is a naturally occurring plasma protein. The 5% concentration is generally used for intravascular volume replacement, while 25% albumin is used when a concentrated colloid is required, including selected cases of hypoalbuminemia, cirrhosis-related complications, and fluid management.
FDA labeling identifies albumin human as a biologic product manufactured from human plasma and subject to pathogen-reduction, screening, fractionation, and release controls. Product labels, rather than brand patents, are the primary source for approved indications and administration requirements. (U.S. Food and Drug Administration, 2023a, 2023b)
How does the commercial positioning of Buminate compare with Flexbumin?
Flexbumin has a clearer association with Takeda's plasma-derived therapies organization and its global plasma collection and fractionation infrastructure. Buminate has a longer Baxter heritage and remains recognized in U.S. hospital formularies, but its financial visibility is lower.
| Commercial factor |
Buminate |
Flexbumin |
| Primary commercial association |
Baxter/Baxalta heritage |
Takeda plasma-derived therapies portfolio |
| Core customers |
Hospitals, intensive-care units, specialty providers |
Hospitals, intensive-care units, specialty providers |
| Main concentrations |
5% and 25% |
5% and 25% |
| Differentiation |
Established brand and hospital familiarity |
Established brand, Takeda supply platform, global portfolio |
| Revenue disclosure |
No standalone public figure |
No standalone public figure |
| Main competitive threat |
Other albumin human suppliers and tenders |
Other albumin human suppliers and tenders |
| Principal barrier to entry |
Plasma supply, validated manufacturing, FDA approval |
Plasma supply, validated manufacturing, FDA approval |
The products compete in a market where purchasing decisions often prioritize contracted price, availability, packaging, concentration, institutional protocols, and supplier reliability. Clinical differentiation between approved albumin products is limited compared with differentiation among branded small-molecule drugs.
What is the FDA regulatory status of Buminate and Flexbumin?
Both products are FDA-regulated biologics approved as albumin human products. Their regulatory position depends on the relevant biologics license or product application, product labeling, manufacturing controls, and post-market compliance.
The FDA-approved labels identify:
- Albumin human as the active ingredient.
- Intravenous administration.
- 5% and 25% concentrations.
- Plasma-derived manufacturing.
- Contraindications and warnings relating to volume overload, hemodilution, allergic reactions, and other risks.
- Storage and handling requirements.
- Approved indications that vary by product label.
Flexbumin is listed in FDA drug-label resources as albumin human supplied by the Takeda/Baxalta commercial organization. Buminate has been associated with Baxter's albumin human product line. Current commercial availability can vary by package size, distributor, national market, and manufacturing status. (U.S. Food and Drug Administration, 2023a, 2023b)
What is the Orange Book status of Buminate and Flexbumin?
Buminate and Flexbumin do not fit the standard Orange Book paradigm used for chemically synthesized prescription drugs.
The Orange Book primarily identifies approved drug products and patent or exclusivity information relevant to abbreviated new drug applications. Plasma-derived biologics are generally evaluated through biologics regulatory pathways and are not treated like ordinary small-molecule products with a standard five-year new chemical entity period followed by routine ANDA competition.
For biologics, the relevant FDA reference is the Purple Book and the applicable Public Health Service Act framework. However, albumin human is an established plasma-derived biologic with a regulatory history that predates modern biosimilar competition. The commercial question is therefore whether another manufacturer can obtain its own approval for albumin human and meet manufacturing, plasma sourcing, analytical, and supply requirements.
A competitor does not necessarily need to wait for a conventional composition-of-matter patent to expire before seeking approval for a separately manufactured albumin human product. Product-specific patents, manufacturing patents, exclusivity rights, facility capacity, and FDA review requirements remain relevant.
What patents protect Buminate and Flexbumin?
The principal commercial protection for Buminate and Flexbumin is not a visible, high-value patent estate comparable to newer biologic medicines.
Publicly available product materials do not establish a meaningful set of active composition-of-matter patents that would independently block all competing albumin human products. Albumin itself is a naturally occurring human plasma protein, which limits the scope for broad composition claims covering the molecule in its native form.
Potential IP categories include:
- Purification and fractionation methods.
- Viral inactivation and pathogen-reduction processes.
- Stabilizers and excipient systems.
- Container and closure systems.
- Concentrated albumin formulations.
- Manufacturing controls and process parameters.
- Packaging and logistics systems.
- Specific methods of use, where claim scope and validity permit.
These categories can create manufacturing friction, but they generally do not provide the same exclusivity profile as a new therapeutic antibody or a novel chemical entity. Publicly available FDA labeling and corporate disclosures do not indicate a material, currently reported patent dispute that determines the U.S. market access of Buminate or Flexbumin.
When did Buminate and Flexbumin lose exclusivity?
Neither product has a single, commercially decisive loss-of-exclusivity date.
Buminate has been marketed for decades, and Flexbumin was introduced into a mature albumin human market. Any original regulatory exclusivity associated with their historical approvals has expired. The current barriers to competition are operational and regulatory rather than a remaining core patent term.
| Exclusivity element |
Buminate |
Flexbumin |
| New chemical entity exclusivity |
Not applicable |
Not applicable |
| Conventional small-molecule five-year period |
Not applicable |
Not applicable |
| Biosimilar exclusivity relevant to current competition |
Limited practical relevance |
Limited practical relevance |
| Core composition patent |
No publicly established blocking estate |
No publicly established blocking estate |
| Key commercial barrier |
Plasma and manufacturing capacity |
Plasma and manufacturing capacity |
| Likely market-access pathway for competitors |
Independent biologic approval or applicable regulatory pathway |
Independent biologic approval or applicable regulatory pathway |
Are there Paragraph IV challenges to Buminate or Flexbumin?
No major publicly reported Paragraph IV litigation is associated with Buminate or Flexbumin in the manner seen with branded small-molecule drugs.
Paragraph IV certifications are part of the abbreviated new drug application framework for patents listed in the Orange Book. Albumin human competition generally does not follow that model. A competing manufacturer would more likely pursue its own biologic approval or other applicable FDA pathway rather than challenge a conventional Orange Book patent protecting albumin human.
The absence of a prominent Paragraph IV case does not eliminate commercial competition. It means the competitive mechanism is more likely to be independent product approval, tender competition, hospital contracting, or substitution among albumin human suppliers.
What manufacturing and supply barriers affect Buminate and Flexbumin?
Plasma availability is the central supply constraint.
Manufacturing albumin human requires:
- Collection of qualified human plasma.
- Donor screening and testing.
- Plasma pooling and fractionation.
- Purification of albumin.
- Viral inactivation and removal controls.
- Sterile filling into validated containers.
- Batch testing and regulatory release.
- Cold-chain or controlled distribution.
The process is capital-intensive and difficult to scale quickly. A new entrant must build or access plasma collection, fractionation, filling, quality-control, and distribution infrastructure. This creates a higher entry barrier than the absence of a strong patent estate might suggest.
Albumin products also face exposure to:
- Plasma donation volumes.
- Donor compensation and collection economics.
- Facility outages.
- Batch failures.
- Regulatory inspections.
- Hospital inventory cycles.
- Government and group-purchasing contracts.
- Transportation and storage constraints.
Takeda's plasma-derived therapies platform gives Flexbumin access to a broader operational network. Buminate's competitive position depends more heavily on the current commercial owner, manufacturing arrangements, and distribution continuity associated with its historical Baxter product line.
What is the financial trajectory for Buminate and Flexbumin?
Standalone revenue for Buminate and Flexbumin is not publicly disclosed in the annual reports of their commercial owners. Takeda reports broader business segments and product groups rather than brand-level sales for Flexbumin. Baxter's historical reporting similarly grouped albumin products within larger pharmaceutical or medical-product categories.
The financial trajectory can therefore be assessed through market drivers rather than exact brand revenue.
| Financial driver |
Expected effect on Buminate and Flexbumin |
| Hospital demand for albumin |
Supports baseline volume |
| Critical-care utilization |
Can increase demand during periods of high hospital acuity |
| Plasma collection costs |
Pressures gross margin |
| Competitor albumin supply |
Pressures price and contract retention |
| Hospital tenders |
Increases price sensitivity |
| Product shortages |
Can shift share rapidly between suppliers |
| Takeda portfolio scale |
Supports Flexbumin supply and commercial reach |
| Mature product status |
Limits premium pricing based solely on innovation |
| Manufacturing compliance costs |
Raises fixed and variable costs |
| New clinical evidence |
Can affect utilization protocols, but not necessarily brand share |
The market is mature and price-sensitive. Revenue growth is more likely to come from volume, geographic expansion, supply reliability, or share capture than from price increases. Margin performance depends on plasma procurement, production yields, facility utilization, and contract pricing.
For Takeda, Flexbumin is unlikely to be a separately material revenue driver relative to the company's major specialty, rare-disease, gastrointestinal, oncology, and plasma-derived products. For Buminate, brand-level revenue exposure is also difficult to quantify because Baxter's business separation and subsequent portfolio transitions changed the reporting structure.
What generic and biosimilar entry risks exist?
The principal risk is substitution by other albumin human products rather than a conventional generic launch.
Potential competitors include manufacturers with:
- Existing plasma fractionation facilities.
- Regional albumin human approvals.
- Government-backed plasma supply.
- Lower manufacturing costs.
- Hospital tender access.
- Established distribution in emerging markets.
Biosimilar terminology has limited practical value for these products. Albumin human is a well-characterized plasma-derived protein, but each manufacturer must demonstrate product quality, safety, consistency, and compliance with applicable FDA requirements. Competition may occur through separately approved products without the legal structure associated with biosimilar interchangeability for newer recombinant biologics.
Which companies compete with Buminate and Flexbumin?
Competition varies by country and procurement channel. Relevant albumin human suppliers have included:
- CSL Behring.
- Grifols.
- Kedrion.
- Octapharma.
- China-based plasma-derived product manufacturers.
- Regional and government-affiliated fractionators.
- Baxter or successor commercial organizations, depending on market and product status.
CSL Behring and Grifols have large plasma-derived product platforms. Their scale can support supply reliability, hospital contracting, and geographic reach. Regional suppliers may compete more effectively on price where local procurement rules favor domestic production.
The competitive landscape is fragmented by jurisdiction. A manufacturer with strong U.S. hospital access may have a different position in Europe, China, Latin America, or the Middle East because albumin procurement and approval rules differ.
What litigation and settlement risks affect Buminate and Flexbumin?
No major publicly reported patent settlement or Paragraph IV settlement is central to the current commercial outlook of either product.
The more relevant legal risks involve:
- Product liability.
- Manufacturing compliance.
- Plasma donor and sourcing rules.
- Contract disputes.
- Regulatory enforcement.
- Supply commitments.
- Hospital tender challenges.
- Product recalls or quality investigations.
A patent litigation event would be commercially significant only if it targeted a specific formulation, purification process, packaging system, or use claim. The absence of a prominent blocking patent case means market access is primarily governed by regulatory approval and manufacturing capacity.
How does the patent strength of Buminate compare with newer biologics?
Buminate and Flexbumin have weaker traditional patent protection than newer biologics such as monoclonal antibodies, long-acting proteins, and engineered fusion products.
| Patent characteristic |
Buminate/Flexbumin |
Newer biologic |
| Natural versus engineered molecule |
Natural human protein |
Often engineered or recombinant |
| Composition patent scope |
Limited |
Frequently broad and central |
| Formulation patent value |
Potentially relevant |
Often layered with device and formulation claims |
| Manufacturing secrecy |
High practical importance |
Important but usually complementary |
| Regulatory exclusivity |
Historical and largely expired |
Often central during launch period |
| Entry barrier |
Plasma and process infrastructure |
Patents, regulatory exclusivity, manufacturing, clinical development |
| Litigation profile |
Limited public patent litigation |
Frequently extensive patent litigation |
The products' economic moat is therefore operational. A competitor with sufficient plasma and manufacturing infrastructure can potentially enter without licensing the brand owner's core molecule patent.
Key Takeaways
- Buminate and Flexbumin are mature, plasma-derived human albumin products.
- Flexbumin is commercially linked to Takeda's global plasma-derived therapies platform.
- Buminate has Baxter and Baxalta heritage but limited current standalone financial disclosure.
- Neither product has a conventional small-molecule Orange Book exclusivity profile.
- No major publicly reported Paragraph IV challenge or patent settlement drives current competition.
- Patent protection is less important than plasma access, fractionation capacity, quality systems, and hospital contracts.
- Product-level revenue is not separately disclosed by Takeda or the historical Baxter/Baxalta reporting structures.
- Revenue growth is likely to depend on volume, supply reliability, geographic reach, and contract share.
- Generic-style competition can arise from separately approved albumin human products.
- The main commercial risk is supplier substitution and price pressure, not a single scheduled patent cliff.
FAQs About Buminate and Flexbumin
Is Flexbumin the same as albumin human?
Yes. Flexbumin contains albumin human, a plasma-derived protein. Its concentration, labeling, packaging, and manufacturing controls distinguish the branded product from other albumin human products.
Is Buminate still protected by patents?
No publicly established blocking patent estate appears to control the broader albumin human molecule. Any remaining protection would more likely involve manufacturing, formulation, packaging, or specific use claims.
Can hospitals substitute another albumin product for Flexbumin?
Substitution depends on the hospital formulary, purchasing contract, applicable state and federal rules, product concentration, labeling, and pharmacy policy. Clinical interchangeability cannot be assumed solely because two products contain albumin human.
Does Takeda disclose Flexbumin revenue?
Takeda does not generally report Flexbumin revenue as a separate line item in its public financial statements. The product is reported within broader business or product categories.
What is the biggest long-term risk to Buminate and Flexbumin?
The largest long-term risks are plasma supply constraints, lower-priced albumin human competitors, hospital tender pressure, manufacturing interruptions, and changes in clinical utilization protocols.
References
-
Takeda Pharmaceutical Company Limited. (2024). Annual report 2024. https://www.takeda.com/investors/financial-results/
-
U.S. Food and Drug Administration. (2023a). Buminate albumin human prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2023b). Flexbumin albumin human prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
Baxter International Inc. (2015). Form 10-K for fiscal year 2015. https://investor.baxter.com/
-
Shire plc. (2018). Annual report 2018. https://www.shire.com/
-
World Health Organization. (2021). WHO guidelines on the production, control and regulation of human plasma for fractionation. World Health Organization.
